Bhanji Muna 4

What Happened

• Director Muna received equity awards from Intellia Therapeutics (NTLA) on June 9, 2026: 9,200 restricted stock units (RSUs) and a 13,300-share option/derivative grant. Both items were reported as grants (code A) with a reported acquisition price of $0.00, meaning no cash was paid by the insider at grant. Total awards cover 22,500 shares on a contingent basis.

Key Details

• Transaction date: June 9, 2026; Form 4 filed June 10, 2026 (within the standard 2-business-day reporting window).
• Grants: 9,200 RSUs (F1); 13,300-share option/derivative award (F2).
• Reported acquisition price: $0.00 for both grants (awarded, not purchased).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes:
  • F1: RSUs represent a contingent right to receive one share per RSU when vested/settled.
  • F2: The 13,300-share award is an option grant that vests in full on the earlier of (a) the first anniversary of the grant or (b) the next annual meeting of stockholders following the grant date.

Context

• These are compensatory equity grants commonly given to directors; they do not represent an open-market purchase or sale and do not involve immediate cash proceeds or dispositions. RSUs convert to common shares when vested; the option award vests per the schedule in F2. Such grants are routine director compensation and should be interpreted as compensation actions rather than direct statements of market sentiment.